



Optimising biomarker-driven therapy in NSCLC: Classroom to Clinic™

Satellite CME Symposium by Liberum IME | IASLC 2022 World Conference on Lung Cancer | Vienna, Austria

Saturday 6 August 2022 | 14:30 – 15:30 CEST | Hall C1

An application has been made to the UEMS EACCME® for CME accreditation of this event.

This symposium has been jointly funded by an educational grant from Bayer Pharmaceuticals, Eli Lilly and Illumina. The content has been developed by the faculty in collaboration with Liberum IME. None of the supporting companies have had any influence on the content or faculty selection.

An interactive symposium with accredited training materials to take away

During this symposium, Professor Fernando López-Ríos and Dr. Robin Cornelissen will provide an overview of the integration of biomarker testing strategies and associated treatment decision making in NSCLC. They will also debut an interactive workshop from the new Classroom to $Clinic^{TM}$ module on biomarker-driven therapy in NSCLC. Delegates can access these free resources online for use with their colleagues.

What is Classroom to Clinic™?

Classroom to Clinic $^{\text{TM}}$ is an international CME-accredited programme providing learning modules curated by experts, designed for your use virtually or in-person for small-group training workshops.

Join us to find out more!

Refreshments will be provided

Faculty



Chair: Professor Fernando López-Ríos Department of Pathology, "12 de Octubre" University Hospital, Spain



Guest Speaker: Dr Robin Cornelissen Pulmonologist, Erasmus MC Cancer Institute, Rotterdam

Learning objectives

- Analyse the role of approved and investigational biomarker-driven therapies in NSCLC
- 2 Apply the latest guideline recommendations around the use of biomarker testing in NSCLC
- 3 Evaluate different strategies for biomarker testing in NSCLC
- Implement strategies to overcome barriers for optimal biomarker testing
- 5 Discuss strategies for overcoming resistance to biomarker-driven therapies in NSCLC

Agenda

Time (CEST)	Presentation	Speaker(s)
14:30-14:35	Welcome, pre-activity information and pre-assessment	Chair: Prof. Fernando López-Ríos
14:35-14:45	Implementation and interpretation of biomarker testing in NSCLC	Prof. Fernando López-Ríos
14:45-14:55	Biomarker-driven approaches: Combined prevalence and individual outcomes	Dr. Robin Cornelissen
14:55-15:00	How to use Classroom to $Clinic^TM$	Prof. Fernando López-Ríos
15:00-15:15	Workshop: Applying guideline best practice to case studies	Prof. Fernando López-Ríos and Dr. Robin Cornelisser
15:15-15:18	Post-assessment and commitment to change	All
15:18-15:25	Q&A session	Prof. Fernando López-Ríos and Dr. Robin Cornelissen
15:25-15:30	Close	Prof. Fernando López-Ríos

This programme was approved by the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer programme committee as an independent activity held in conjunction with the IASLC 2022 World Conference on Lung Cancer. This programme is not sponsored or endorsed by IASLC and is not part of the official IASLC-accredited programme. Liberum IME is an independent medical education agency that creates bespoke, innovative programmes that follow the core principles of good CME practice. We are dedicated to sharing best practice through international collaboration, allowing healthcare professionals worldwide to put science into practice.

CME, continuing medical education; EACCME, European Accreditation Council for Continuing Medical Education; NSCLC, non-small cell lung cancer; UEMS, European Union of Medical Specialists.